-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 26, Lilly issued a statement terminating the ACTIV-3 clinical study, which recently showed that its new coronal and antibody LY-CoV555 (bamlanivimab) was unlikely to improve late recovery in hospitalized COVID-19 patients.
the study was conducted by the National Institutes of Health (NIH) and the American Institute of Allergy and Infectious Diseases (NIAID).
other clinical studies of Bamlanivimab are still ongoing, including the ACTIV-2 study (treating patients with mild to moderate COVID-19) and the BLAZE-2 study (the prevention of PHASE III clinical trials of COVID-19).
, Lilly has filed an emergency authorization application with the FDA based on BLAZE-1 research data.
Lilly said that while there is insufficient evidence that bamlanivimab combination therapy can improve clinical outcomes in patients hospitalized with COVID-19, based on positive data from the BLAZE-1 study, Lilly believes Bamlanivimab may prevent early progression of COVID-19.
